title: Improvement in fluoxetine-associated sexual dysfunction in patients switched to bupropion.
abstract: BACKGROUND
  This study was conducted to determine the effect of bupropion on the sexual functioning of male and female outpatients who developed anorgasmia or delayed orgasm while receiving fluoxetine treatment for depression.
  
  
  METHODS
  Thirty-nine patients who satisfied criteria for participation in the study discontinued fluoxetine treatment and entered a 2-week washout phase followed by an open 8-week bupropion treatment phase. Three parameters of sexual functioning were followed throughout the study: orgasm function, libido, and satisfaction with overall sexual functioning. Depression was also evaluated at each visit.
  
  
  RESULTS
  All patients reported orgasm delay and/or failure at the time of fluoxetine discontinuation. Orgasm function, libido, and satisfaction with sexual functioning improved during the 2-week fluoxetine washout period and during the bupropion treatment phase. Ninety-four percent of patients (29/31) had complete or partial resolution of their orgasm dysfunction at the end of bupropion treatment, and 81% of patients (25/31) were "much" or "very much" more satisfied with their overall sexual functioning. Most patients entered the study with decreased libido on fluoxetine. Libido was "much" or "very much" increased for 81% of patients (25/31) at the end of the study. In addition, depression scores on the Hamilton Rating Scale for Depression and Clinical Global Impressions-Severity scale significantly improved during the bupropion treatment phase. Finally, bupropion was well tolerated by most patients.
  
  
  CONCLUSIONS
  Bupropion may be an appropriate antidepressant for patients who develop sexual dysfunction during fluoxetine treatment or for whom sexual dysfunction is a concern.
authors.affiliation: Department of Psychiatry, University of Tennessee, Memphis.
authors.forename: P W
authors.initials: PW
authors.lastname: Walker
authors.forename: J O
authors.initials: JO
authors.lastname: Cole
authors.forename: E A
authors.initials: EA
authors.lastname: Gardner
authors.forename: A R
authors.initials: AR
authors.lastname: Hughes
authors.forename: J A
authors.initials: JA
authors.lastname: Johnston
authors.forename: S R
authors.initials: SR
authors.lastname: Batey
authors.forename: C G
authors.initials: CG
authors.lastname: Lineberry
mesh_terms: D000553:Ambulatory Care; D016642:Bupropion / Q000494:pharmacology / Q000627:therapeutic use*; D003866:Depressive Disorder / Q000188:drug therapy*; D005260:Female; D005473:Fluoxetine / Q000009:adverse effects* / Q000627:therapeutic use; D006801:Humans; D007989:Libido / Q000187:drug effects; D008297:Male; D008875:Middle Aged; D009948:Orgasm / Q000187:drug effects*; D010549:Personal Satisfaction; D011569:Psychiatric Status Rating Scales; D012720:Severity of Illness Index; D020018:Sexual Dysfunctions, Psychological / Q000139:chemically induced* / Q000188:drug therapy / Q000523:psychology; D016896:Treatment Outcome
chemical_list: D005473:Fluoxetine; D016642:Bupropion